Search
Research
The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adultsWe report the case of a 45-year-old woman who was diagnosed with a NOS based on immunohistochemical analysis of the patient's tumor at diagnosis.
Research
Exposure to professional pest control treatments and the risk of childhood acute lymphoblastic leukemiaPrevious studies suggest that exposure to pesticides increases the risk of childhood acute lymphoblastic leukemia
Research
Pediatric meningioma: Current approaches and future directionWith improvement in leukemia therapy, central nervous system (CNS) tumors are the leading cause of cancer mortality in children and the most expensive...
Research
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growthAnti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory.
News & Events
Delivering smart drugs into cellsThe Drug Discovery Unit has been finding ways for smart drugs to penetrate deep into cells and attacking their disease targets while causing fewer side effects
News & Events
New test proves effective in more cancersAvantogen Limited (ACU:ASX) today announced that cancer researchers at Perth's The Kids for Child Health Research (TICHR) and Avantogen Limited
News & Events
National study to unravel triggers for childhood leukaemiaA national study is investigating diet, chemical exposure and genetic factors in a new bid to unravel the causes of childhood leukaemia.
Research
Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patientsAll children who are receiving therapy for cancer should receive a single dose of PCV13 as soon as possible after diagnosis, regardless of prior PCV exposure.
Research
Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine modelsThis JAK3A572V knockin model is a relevant new tool for testing the efficacy of JAK inhibitors in JAK3-related hematopoietic malignancies